Search results
Results from the WOW.Com Content Network
The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) is a brief neuropsychological assessment used to assess the severity of cognitive symptoms of dementia. It is one of the most widely used cognitive scales in clinical trials [ 1 ] and is considered to be the “gold standard” for assessing antidementia treatments.
Amyloid-related imaging abnormalities (ARIA) are abnormal differences seen in magnetic resonance imaging of the brain in patients with Alzheimer's disease. ARIA is associated with anti-amyloid drugs, particularly human monoclonal antibodies such as aducanumab. [1] There are two types of ARIA: ARIA-E and ARIA-H.
The diagnosis of Alzheimer's disease typically requires a microscopic analysis of plaques and tangles in brain tissue, usually at autopsy. [40] However, Aβ plaques (along with cerebral Aβ-amyloid angiopathy ) can be detected in the brains of living subjects by preparing radiolabeled agents that bind selectively to Aβ deposits in the brain ...
The free online conference runs from 10 a.m. to 12:30 p.m. Wednesday, and is sponsored by the Alzheimer's Foundation of America. Alzheimer's is one of the top causes of death in the United States ...
Alzheimer’s Disease International (ADI) is a not-for-profit, international federation of Alzheimer and dementia associations from around the world. The organization is in official relations with the World Health Organization (WHO). [1] ADI advocates for people living with Alzheimer’s disease and all other types of dementia.
A new test may help predict who is at risk for Alzheimer's disease. ABC explains, "It measures a patient's risk of mental impairment based on several factors, including how quickly the patient can ...
With increasing clinical focus on dementia, there is likewise increasing interest in pharmacology in the development of drugs to halt, or slow the progression of dementia-related illness such as Alzheimer's Disease. Therefore, early and accurate diagnosis of dementia and staging can be essential to proper clinical care.
Recent research has shown that large soluble APP (sAPP) [9] that are present in CSF may serve as a novel potential biomarker of Alzheimer's disease. In an article published in Nature, a group led by Lewczuk performed a test to observe the performance of a soluble form of APP α and β. A significant increase in sAPP α and sAPP β was found in ...